ClinicalTrials.gg
CompletedNCT05007808Updated Apr 23, 2024Results posted

Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee

A Phase 2 interventional study of G001 Topical Gel and Vehicle in Osteoarthritis, Knee, sponsored by BUZZZ Pharmaceuticals Limited. Completed at 10 sites in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by BUZZZ Pharmaceuticals Limited · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jan 2021, registered Jul 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 171 studies in Osteoarthritis, Knee with a site in Canada — 28 open to participants now, 41 under way, 6 of them phase 3. Osteoarthritis, Knee · Canada.

Enrollment
29th of 160
210 · median 65
Started
2021
with 8 others
Phase 2
19 of 171
none open now
Registered
120th of 171
by date

Among the 171 studies in Osteoarthritis, Knee with a site in Canada, this one is the 29th largest by enrollment of the 160 interventional ones that give a count, is one of 9 that started in 2021, is one of 19 in phase 2, and was the 120th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

28 of the 171 studies in Osteoarthritis, Knee with a site in Canada are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Osteoarthritis, Knee with a site in Canada, or all of them as a file.
02

Study summary

Phase 2 multicenter, double-blind, randomized, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, and local tolerability of G001 topical gel compared to matching Vehicle topical gel in patients with symptomatic OA of the knee.

Each patient's participation is approximately 7 weeks (\~1 week screening, 4 weeks of treatment, and 2 weeks of post-treatment follow-up). Eligible patients with adequate OA pain in the index knee are randomized (1:1 allocation ratio) at the Baseline/Flare Visit 1.

Following screening, prior NSAID and/or acetaminophen use is discontinued to allow for washout and symptom flare. Patients are instructed to rate their worst daily and nightly pain in their daily diary, as well as to document all study drug applications and any rescue medication (acetaminophen) use for breakthrough pain. Acetaminophen may be used as rescue medication only, except within 12 hours prior to the Baseline Visit and within 12 hours prior to any post-baseline efficacy assessments (Weeks 2, 4, and 5). Patients are instructed to return to the clinic 3 to 7 days after the last study drug application for Flare Visit 2, and within approximately 2 weeks after the last study drug application for end-of-study evaluations.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • osteoarthritis
  • knee
  • topical therapy
  • pain
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of OA of the knee, meeting American College of Rheumatology (ACR) criteria for classification of idiopathic (primary) OA for at least 6 months prior to Screening
  • Radiologic evidence of OA of the knee of grade 2 (mild) or grade 3 (moderate) according to Kellgren and Lawrence Radiographic Grading
  • Worst daily pain (within 24 hours prior to Screening and Baseline) in the index knee between 4 and 8 on the 11-point pain NRS
  • On stable analgesic therapy

At Baseline:

  • Development of a flare of pain following washout of stable analgesic (NSAID and/or acetaminophen) therapy

Exclusion criteria

Exclusion Criteria:

  • Radiologic evidence of severe OA of the knee (Kellgren and Lawrence grade 4)
  • Secondary OA of the index knee
  • Any other arthritis, included but not limited to rheumatoid arthritis, psoriatic arthritis, etc.
  • History of pseudo-gout or inflammatory flare-ups
  • History of severe neurological conditions
  • Any other chronic pain conditions (e.g., back pain) or disabling conditions affecting the joints
  • Patients who are non-ambulatory or require the use of crutches or a walker, or started using a cane within 30 days prior to Screening
  • Any history of major surgery to the index knee, minor knee surgery, or injury to the index knee within 1 year prior to Screening
  • Knee arthroscopy (index knee) within 3 months prior to Screening
  • Planned or candidate for knee replacement or knee reconstruction surgery
  • Received intra-articular viscosupplementation/hyaluronate, joint lavage, or other invasive therapies to the index knee in the past 90 days
  • Treatment with or need for any of the following: (1) oral or intramuscular within the past 90 days; (2) intra-articular corticosteroid injection into the index knee within the past 90 days, or into any other joint within the past 30 days; (3) current use of topical corticosteroids on the index knee
  • Prior stable therapy with an opioid analgesic, or anticipated need for opioid analgesic use during the study
  • Use of sedative hypnotic medication, antidepressants with known analgesic effect, antipsychotics, antiepileptics, and anti-Parkinson drugs within the past 14 days
  • Regular use of medication for headaches
  • Anticipated use of any oral or topical NSAID (apart from the study drug) during the study
  • Known sensitivity to the study drug (or any of its ingredients), or NSAIDs, or presence of , warnings, or precautions

At Baseline:

  • Worst daily pain (within the past 24 hours) in the contralateral knee assessed as >2 on the 11-point pain NRS scale
  • Non-compliance with the daily diary requirement during the Screening period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    G001 Topical Gel

    G001 Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.

    Drug: G001 Topical Gel

  • Placebo comparator
    Vehicle Topical Gel

    Vehicle Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.

    Drug: Vehicle

Interventions

  • DrugG001 Topical Gel

    Non-steroidal anti-inflammatory drug for topical administration

  • DrugVehicle

    Vehicle Gel for topical administration

06

What researchers measure

Primary outcomes

  1. Change From Baseline in WOMAC Pain Subscale Score at Week 4/EOT

    Changes from Baseline in WOMAC Pain Subscale Score (5-item scale, score range 0-20, with higher scores indicating worse outcome)

    Time frame: Week 4

Secondary outcomes

  1. Worst Daytime Pain Severity Scores (11-point Pain NRS), Based on Daily Diary Recordings

    Changes from Baseline to Week 4 in Worst Daytime Pain Severity Scores on a 0-10 scale, with higher scores indicating worse outcome

    Time frame: Week 4

  2. Worst Nighttime Pain Severity Score (11-point NRS), Based on Daily Diary Recordings

    Changes from Baseline to Week 4 in Worst Nighttime Pain Severity Scores recorded on a 0-10 scale, with higher scores indicating worse outcome

    Time frame: Week 4

  3. Percent Reduction From Baseline in Worst Daytime Pain

    Percentage of Patients Achieving ≥ 20%, ≥ 30%, and ≥ 50% Reduction from Baseline in Worst Daytime Pain at Week 4/EOT

    Time frame: Week 4

  4. Percent Reduction From Baseline in Worst Nighttime Pain

    Percentage of Patients Achieving ≥ 20%, ≥ 30%, and ≥ 50% Reduction from Baseline in Worst Nighttime Pain at Week 4/EOT

    Time frame: Week 4

  5. Change From Baseline in WOMAC Physical Function Subscale Score at Week 4/EOT

    WOMAC Physical Function Subscale (17-item, score range 0-68, with higher scores indicating worse outcome)

    Time frame: Week 4

  6. Change From Baseline in WOMAC Total Score at Week 4/EOT

    WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome)

    Time frame: Week 4

  7. Change From Baseline in WOMAC Stiffness Subscale Score at Week 4/EOT

    WOMAC Stiffness Subscale (2-item, range of scores 0-8, with higher scores indicating worse outcome)

    Time frame: Week 4

  8. Change From Baseline in WOMAC Total and Subscale Scores at Week 2

    Change from Baseline to Week 2 in: WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome) WOMAC Pain Subscale score (5-item, score range 0-20, with higher scores indicating worse pain) WOMAC Stiffness Subscale score (2-item, score range 0-8, with higher scores indicating worse stiffness) WOMAC Physical Function Subscale score (17-item, score range 0-68, with higher scores indicating worse physical function)

    Time frame: Week 2

  9. Change From Week 4 to Week 5 in WOMAC Total and Subscale Scores

    Change from Week 4/EOT to Week 5/Flare Visit 2 (FV2) in: WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome) WOMAC Pain Subscale score (5-item, score range 0-20, with higher scores indicating worse pain) WOMAC Stiffness Subscale score (2-item, score range 0-8, with higher scores indicating worse stiffness) WOMAC Physical Function Subscale score (17-item, score range 0-68, with higher scores indicating worse physical function)

    Time frame: Week 4 to Week 5

  10. Change From Baseline in Patient Global Assessment (PGA) of Disease Activity Over Time

    PGA of Disease Activity (DA) was assessed on a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor), with higher scores indicating worse outcome. Change from Baseline in PGA of disease activity scores was calculated and the response was classified into 3 categories according to the following rules: Improved - defined as either of the following: * For baseline Grade ≥ 2: a reduction of ≥ 2 grades from baseline * For baseline Grade = 1: a change in grade from 1 to 0 Worsened - defined as either of the following: * For baseline Grade ≤ 2: an increase of ≥ 2 grades from baseline * For baseline Grade = 3: a change in grade from 3 to 4 No Change - defined as neither Improved nor Worsened

    Time frame: Weeks 2, 4 and 5

  11. Change From Baseline in Investigator Global Assessment (IGA) of Disease Activity Over Time

    IGA of Disease Activity (DA) was assessed on a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor), with higher scores indicating worse outcome. Change from Baseline in IGA of disease activity scores was calculated and the response was classified into 3 categories according to the following rules: Improved - defined as either of the following: * For baseline Grade ≥ 2: a reduction of ≥ 2 grades from baseline * For baseline Grade = 1: a change in grade from 1 to 0 Worsened - defined as either of the following: * For baseline Grade ≤ 2: an increase of ≥ 2 grades from baseline * For baseline Grade = 3: a change in grade from 3 to 4 No Change - defined as neither Improved nor Worsened

    Time frame: Weeks 2, 4 and 5

  12. PGA of Overall Treatment Benefit (OTB)

    PGA of overall treatment benefit was completed using a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor) after 2 and 4 weeks of treatment, with higher scores indicating worse outcome.

    Time frame: Weeks 2 and 4

  13. IGA of Overall Treatment Benefit (OTB)

    IGA of overall treatment benefit was completed using a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor) after 2 and 4 weeks of treatment, with higher scores indicating worse outcome.

    Time frame: Weeks 2 and 4

  14. Rescue Medication Use

    Only acetaminophen was permitted as rescue medication (up to 500 mg per dose and 2000 mg/day to manage breakthrough pain). No rescue medication use was allowed within 12 hours before an efficacy assessment.

    Time frame: 5 weeks

  15. Number of Rescue Medication Doses

    Only acetaminophen was permitted as rescue medication (up to 500 mg per dose and 2000 mg/day to manage breakthrough pain). No rescue medication use was allowed within 12 hours before an efficacy assessment.

    Time frame: 5 weeks

Other outcomes

  1. Number of Participants With AEs, Study Drug-related AEs, Serious AEs, and AEs Leading to Study Drug Discontinuation

    Number and percentage of participants with adverse events (AEs), study drug-related AEs, serious AEs, and AEs leading to study drug discontinuation

    Time frame: 6 weeks

  2. Frequency and Severity of Application Site AEs

    Number and percentage of participants with application site AEs

    Time frame: 6 weeks

  3. Skin Irritation Test Scores (Berger/Bowman Scoring Scale)

    The Numerical Total Score is the sum of the Dermal Response score (from 0=No evidence of irritation to 7=Strong reaction spreading beyond the application site) and the numeric equivalent of Other Effects score (from 0=Slightly glazed appearance to 3=Small petechial erosions and/or scabs). The Numerical Total Score range is from 0 to 10, with higher scores indicating worse outcome/skin irritation.

    Time frame: Weeks 2, 4, and 6

  4. ECG Abnormalities in QT, QTc, QRS, or PR Intervals

    Number and percentage of participants with clinically significant (CS) abnormal results in QT, QTc, QRS, or PR intervals at Week 4/EOT

    Time frame: 4 weeks

  5. Changes From Baseline in Safety Laboratory Test Results

    Mean changes (descriptive) and shifts from normal baseline to laboratory values outside reference ranges

    Time frame: 6 weeks

  6. Changes in Vital Signs Measurements

    Mean changes (descriptive) from baseline

    Time frame: 6 weeks

  7. Changes in Physical Examination

    Number and percentage of participants with clinically significant abnormal findings

    Time frame: 6 weeks

07

Results

Posted Apr 23, 2024

Participant flow

The study was conducted at 10 study centers in Canada. A total of 210 patients with OA of the knee were randomly assigned to double-blinded treatment in the study; of these, 105 patients received G001 and 105 patients received Vehicle.

Participant flow — Overall Study
MilestoneG001 Topical GelVehicle Topical Gel
Started105105
Completed99100
Not completed65

Outcome measures

PrimaryChange From Baseline in WOMAC Pain Subscale Score at Week 4/EOT

Changes from Baseline in WOMAC Pain Subscale Score (5-item scale, score range 0-20, with higher scores indicating worse outcome)

Time frame:
Week 4
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Pain Subscale Score at Week 4/EOT
score on a scaleG001 Topical GelVehicle Topical Gel
Change From Baseline in WOMAC Pain Subscale Score at Week 4/EOT-5.4 ± 0.32-5.2 ± 0.32
Statistical analysis
  • G001 Topical Gel vs Vehicle Topical Gel · t-test, 2 sided · p = 0.6742 · Ls mean difference: -0.19 · 95% CI -1.081 to 0.701
SecondaryWorst Daytime Pain Severity Scores (11-point Pain NRS), Based on Daily Diary Recordings

Changes from Baseline to Week 4 in Worst Daytime Pain Severity Scores on a 0-10 scale, with higher scores indicating worse outcome

Time frame:
Week 4
Reported as:
Mean · score on a scale
Worst Daytime Pain Severity Scores (11-point Pain NRS), Based on Daily Diary Recordings
score on a scaleG001 Topical GelVehicle Topical Gel
Worst Daytime Pain Severity Scores (11-point Pain NRS), Based on Daily Diary Recordings-2.1 ± 2.01-2.0 ± 2.07
SecondaryWorst Nighttime Pain Severity Score (11-point NRS), Based on Daily Diary Recordings

Changes from Baseline to Week 4 in Worst Nighttime Pain Severity Scores recorded on a 0-10 scale, with higher scores indicating worse outcome

Time frame:
Week 4
Reported as:
Mean · score on a scale
Worst Nighttime Pain Severity Score (11-point NRS), Based on Daily Diary Recordings
score on a scaleG001 Topical GelVehicle Topical Gel
Worst Nighttime Pain Severity Score (11-point NRS), Based on Daily Diary Recordings-2.1 ± 2.01-1.9 ± 2.04
SecondaryPercent Reduction From Baseline in Worst Daytime Pain

Percentage of Patients Achieving ≥ 20%, ≥ 30%, and ≥ 50% Reduction from Baseline in Worst Daytime Pain at Week 4/EOT

Time frame:
Week 4
Reported as:
Count of participants · Participants
Percent Reduction From Baseline in Worst Daytime Pain
ParticipantsG001 Topical GelVehicle Topical Gel
≥ 20% Reduction from BL7068
≥ 30% Reduction from BL5853
≥ 50% Reduction from BL3536
SecondaryPercent Reduction From Baseline in Worst Nighttime Pain

Percentage of Patients Achieving ≥ 20%, ≥ 30%, and ≥ 50% Reduction from Baseline in Worst Nighttime Pain at Week 4/EOT

Time frame:
Week 4
Reported as:
Count of participants · Participants
Percent Reduction From Baseline in Worst Nighttime Pain
ParticipantsG001 Topical GelVehicle Topical Gel
≥ 20% Reduction from BL7365
≥ 30% Reduction from BL5956
≥ 50% Reduction from BL3635
SecondaryChange From Baseline in WOMAC Physical Function Subscale Score at Week 4/EOT

WOMAC Physical Function Subscale (17-item, score range 0-68, with higher scores indicating worse outcome)

Time frame:
Week 4
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Physical Function Subscale Score at Week 4/EOT
score on a scaleG001 Topical GelVehicle Topical Gel
Change From Baseline in WOMAC Physical Function Subscale Score at Week 4/EOT-12.5 ± 1.07-10.4 ± 1.06
SecondaryChange From Baseline in WOMAC Total Score at Week 4/EOT

WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome)

Time frame:
Week 4
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Total Score at Week 4/EOT
score on a scaleG001 Topical GelVehicle Topical Gel
Change From Baseline in WOMAC Total Score at Week 4/EOT-19.4 ± 1.47-17.1 ± 1.46
SecondaryChange From Baseline in WOMAC Stiffness Subscale Score at Week 4/EOT

WOMAC Stiffness Subscale (2-item, range of scores 0-8, with higher scores indicating worse outcome)

Time frame:
Week 4
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Stiffness Subscale Score at Week 4/EOT
score on a scaleG001 Topical GelVehicle Topical Gel
Change From Baseline in WOMAC Stiffness Subscale Score at Week 4/EOT-1.6 ± 0.14-1.5 ± 0.14
SecondaryChange From Baseline in WOMAC Total and Subscale Scores at Week 2

Change from Baseline to Week 2 in: WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome) WOMAC Pain Subscale score (5-item, score range 0-20, with higher scores indicating worse pain) WOMAC Stiffness Subscale score (2-item, score range 0-8, with higher scores indicating worse stiffness) WOMAC Physical Function Subscale score (17-item, score range 0-68, with higher scores indicating worse physical function)

Time frame:
Week 2
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Total and Subscale Scores at Week 2
score on a scaleG001 Topical GelVehicle Topical Gel
WOMAC Total score, Change from BL to Week 2-15.7 ± 1.27-13.2 ± 1.25
WOMAC Pain score, Change from BL to Week 2-4.7 ± 0.29-4.4 ± 0.29
WOMAC Stiffness score, Change from BL to Week 2-1.4 ± 0.13-1.0 ± 0.13
WOMAC Physical Function score, Change from BL to Week 2-9.5 ± 0.93-8.0 ± 0.91
SecondaryChange From Week 4 to Week 5 in WOMAC Total and Subscale Scores

Change from Week 4/EOT to Week 5/Flare Visit 2 (FV2) in: WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome) WOMAC Pain Subscale score (5-item, score range 0-20, with higher scores indicating worse pain) WOMAC Stiffness Subscale score (2-item, score range 0-8, with higher scores indicating worse stiffness) WOMAC Physical Function Subscale score (17-item, score range 0-68, with higher scores indicating worse physical function)

Time frame:
Week 4 to Week 5
Reported as:
Least squares mean · score on a scale
Change From Week 4 to Week 5 in WOMAC Total and Subscale Scores
score on a scaleG001 Topical GelVehicle Topical Gel
WOMAC Total score, Change from Week 4/EOT to Week 5/FV23.5 ± 0.892.7 ± 0.89
WOMAC Pain score, Change from Week 4/EOT to Week 5/FV20.8 ± 0.210.7 ± 0.21
WOMAC Stiffness score, Change from Week 4/EOT to Week 5/FV20.3 ± 0.100.3 ± 0.10
WOMAC Physical Function score, Change from Week 4/EOT to Week 5/FV22.4 ± 0.651.7 ± 0.65
SecondaryChange From Baseline in Patient Global Assessment (PGA) of Disease Activity Over Time

PGA of Disease Activity (DA) was assessed on a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor), with higher scores indicating worse outcome. Change from Baseline in PGA of disease activity scores was calculated and the response was classified into 3 categories according to the following rules: Improved - defined as either of the following: * For baseline Grade ≥ 2: a reduction of ≥ 2 grades from baseline * For baseline Grade = 1: a change in grade from 1 to 0 Worsened - defined as either of the following: * For baseline Grade ≤ 2: an increase of ≥ 2 grades from baseline * For baseline Grade = 3: a change in grade from 3 to 4 No Change - defined as neither Improved nor Worsened

Time frame:
Weeks 2, 4 and 5
Reported as:
Count of participants · Participants
Change From Baseline in Patient Global Assessment (PGA) of Disease Activity Over Time
ParticipantsG001 Topical GelVehicle Topical Gel
PGA of DA, Change from BL to Week 2 — Improved2420
PGA of DA, Change from BL to Week 2 — No change7479
PGA of DA, Change from BL to Week 2 — Worsened13
PGA of DA, Change from BL to Week 4 — Improved3828
PGA of DA, Change from BL to Week 4 — No change6472
PGA of DA, Change from BL to Week 4 — Worsened04
PGA of DA, Change from BL to Week 5 — Improved2621
PGA of DA, Change from BL to Week 5 — No change7375
PGA of DA, Change from BL to Week 5 — Worsened14
SecondaryChange From Baseline in Investigator Global Assessment (IGA) of Disease Activity Over Time

IGA of Disease Activity (DA) was assessed on a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor), with higher scores indicating worse outcome. Change from Baseline in IGA of disease activity scores was calculated and the response was classified into 3 categories according to the following rules: Improved - defined as either of the following: * For baseline Grade ≥ 2: a reduction of ≥ 2 grades from baseline * For baseline Grade = 1: a change in grade from 1 to 0 Worsened - defined as either of the following: * For baseline Grade ≤ 2: an increase of ≥ 2 grades from baseline * For baseline Grade = 3: a change in grade from 3 to 4 No Change - defined as neither Improved nor Worsened

Time frame:
Weeks 2, 4 and 5
Reported as:
Count of participants · Participants
Change From Baseline in Investigator Global Assessment (IGA) of Disease Activity Over Time
ParticipantsG001 Topical GelVehicle Topical Gel
IGA of DA, Change from BL to Week 2 — Improved2422
IGA of DA, Change from BL to Week 2 — No Change7477
IGA of DA, Change from BL to Week 2 — Worsened13
IGA of DA, Change from BL to Week 4 — Improved3929
IGA of DA, Change from BL to Week 4 — No Change6372
IGA of DA, Change from BL to Week 4 — Worsened13
IGA of DA, Change from BL to Week 5 — Improved3021
IGA of DA, Change from BL to Week 5 — No Change6778
IGA of DA, Change from BL to Week 5 — Worsened31
SecondaryPGA of Overall Treatment Benefit (OTB)

PGA of overall treatment benefit was completed using a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor) after 2 and 4 weeks of treatment, with higher scores indicating worse outcome.

Time frame:
Weeks 2 and 4
Reported as:
Count of participants · Participants
PGA of Overall Treatment Benefit (OTB)
ParticipantsG001 Topical GelVehicle Topical Gel
PGA of OTB at Week 2 — Good or Very Good3239
PGA of OTB at Week 2 — Fair4947
PGA of OTB at Week 2 — Poor or Very Poor1816
PGA of OTB at Week 4 — Good or Very Good5046
PGA of OTB at Week 4 — Fair3638
PGA of OTB at Week 4 — Poor or Very Poor1620
SecondaryIGA of Overall Treatment Benefit (OTB)

IGA of overall treatment benefit was completed using a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor) after 2 and 4 weeks of treatment, with higher scores indicating worse outcome.

Time frame:
Weeks 2 and 4
Reported as:
Count of participants · Participants
IGA of Overall Treatment Benefit (OTB)
ParticipantsG001 Topical GelVehicle Topical Gel
IGA of OTB, Week 2 — Very Good or Good3240
IGA of OTB, Week 2 — Fair4747
IGA of OTB, Week 2 — Poor or Very Poor2015
IGA of OTB, Week 4 — Very Good or Good5246
IGA of OTB, Week 4 — Fair3539
IGA of OTB, Week 4 — Poor or Very Poor1619
SecondaryRescue Medication Use

Only acetaminophen was permitted as rescue medication (up to 500 mg per dose and 2000 mg/day to manage breakthrough pain). No rescue medication use was allowed within 12 hours before an efficacy assessment.

Time frame:
5 weeks
Reported as:
Mean · mg/day
Rescue Medication Use
mg/dayG001 Topical GelVehicle Topical Gel
Rescue Medication Use71.6 ± 66.6594.6 ± 123.3
Other pre-specifiedNumber of Participants With AEs, Study Drug-related AEs, Serious AEs, and AEs Leading to Study Drug Discontinuation

Number and percentage of participants with adverse events (AEs), study drug-related AEs, serious AEs, and AEs leading to study drug discontinuation

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs, Study Drug-related AEs, Serious AEs, and AEs Leading to Study Drug Discontinuation
ParticipantsG001 Topical GelVehicle Topical Gel
Any TEAE3628
Treatment-related TEAEs54
Any SAE01
Any TEAE leading to Discontinuation31
Other pre-specifiedFrequency and Severity of Application Site AEs

Number and percentage of participants with application site AEs

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Frequency and Severity of Application Site AEs
ParticipantsG001 Topical GelVehicle Topical Gel
Frequency and Severity of Application Site AEs01
Other pre-specifiedSkin Irritation Test Scores (Berger/Bowman Scoring Scale)

The Numerical Total Score is the sum of the Dermal Response score (from 0=No evidence of irritation to 7=Strong reaction spreading beyond the application site) and the numeric equivalent of Other Effects score (from 0=Slightly glazed appearance to 3=Small petechial erosions and/or scabs). The Numerical Total Score range is from 0 to 10, with higher scores indicating worse outcome/skin irritation.

Time frame:
Weeks 2, 4, and 6
Reported as:
Count of participants · Participants
Skin Irritation Test Scores (Berger/Bowman Scoring Scale)
ParticipantsG001 Topical GelVehicle Topical Gel
Skin Irritation Total Score, Week 2 — Numerical Total Score of 098101
Skin Irritation Total Score, Week 2 — Numerical Total Score of 110
Skin Irritation Total Score, Week 2 — Numerical Total Score of ≥211
Skin Irritation Total Score, Week 4/EOT — Numerical Total Score of 0101103
Skin Irritation Total Score, Week 4/EOT — Numerical Total Score of 111
Skin Irritation Total Score, Week 4/EOT — Numerical Total Score of ≥210
Skin Irritation Total Score, Week 6 — Numerical Total Score of 0101101
Skin Irritation Total Score, Week 6 — Numerical Total Score of 100
Skin Irritation Total Score, Week 6 — Numerical Total Score of ≥200
Other pre-specifiedECG Abnormalities in QT, QTc, QRS, or PR Intervals

Number and percentage of participants with clinically significant (CS) abnormal results in QT, QTc, QRS, or PR intervals at Week 4/EOT

Time frame:
4 weeks
Reported as:
Count of participants · Participants
ECG Abnormalities in QT, QTc, QRS, or PR Intervals
ParticipantsG001 Topical GelVehicle Topical Gel
CS QT Interval abnormality00
CS QTc Interval abnormality00
CS QRS Interval abnormality00
CS PR Interval abnormality00
Other pre-specifiedChanges From Baseline in Safety Laboratory Test Results

Mean changes (descriptive) and shifts from normal baseline to laboratory values outside reference ranges

Time frame:
6 weeks

Results for this outcome have not been posted.

Other pre-specifiedChanges in Vital Signs Measurements

Mean changes (descriptive) from baseline

Time frame:
6 weeks

Results for this outcome have not been posted.

Other pre-specifiedChanges in Physical Examination

Number and percentage of participants with clinically significant abnormal findings

Time frame:
6 weeks

Results for this outcome have not been posted.

SecondaryNumber of Rescue Medication Doses

Only acetaminophen was permitted as rescue medication (up to 500 mg per dose and 2000 mg/day to manage breakthrough pain). No rescue medication use was allowed within 12 hours before an efficacy assessment.

Time frame:
5 weeks
Reported as:
Mean · number of doses
Number of Rescue Medication Doses
number of dosesG001 Topical GelVehicle Topical Gel
Number of Rescue Medication Doses5.9 ± 6.037.9 ± 12.54

Adverse events

Collected over Adverse event (AE) collection period: from the Screening Visit (Day -7 to -3) to the Week 6/End-of-Study (EOS) Visit (Day 43 +/-3). Analyses of AEs were performed for treatment-emergent events (TEAEs), defined as any AE with onset during or after the first application of study drug through the end of the study (Week 6/EOS visit), or any event that was present at Baseline but worsened in severity during or after the first application of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
G001 Topical Gel0/105 (0%)0/105 (0%)10/105 (9.5%)
Vehicle Topical Gel0/105 (0%)1/105 (1%)5/105 (4.8%)
Most frequent serious events
Most frequent serious events
EventG001 Topical GelVehicle Topical Gel
Atrial fibrillationCardiac disorders0/1051/105
Most frequent other events
Most frequent other events
EventG001 Topical GelVehicle Topical Gel
HeadacheNervous system disorders10/1055/105

Baseline characteristics

Age, Continuous
Age, Continuous(years)G001 Topical GelVehicle Topical GelTotal
Mean64.3 ± 7.8965.3 ± 8.3564.8 ± 8.12
Sex: Female, Male
Sex: Female, Male(Participants)G001 Topical GelVehicle Topical GelTotal
Female6461125
Male414485
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)G001 Topical GelVehicle Topical GelTotal
Hispanic or Latino101
Not Hispanic or Latino104105209
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)G001 Topical GelVehicle Topical GelTotal
American Indian or Alaska Native000
Asian171027
Native Hawaiian or Other Pacific Islander000
Black or African American369
White8389172
More than one race000
Unknown or Not Reported202
Region of Enrollment
Region of Enrollment(participants)G001 Topical GelVehicle Topical GelTotal
Canada105105210
Worst daily pain (11-point NRS), Index knee
Worst daily pain (11-point NRS), Index knee(Score on a scale)G001 Topical GelVehicle Topical GelTotal
Mean6.8 ± 1.296.4 ± 1.396.6 ± 1.35
Worst daily pain (11-point NRS), Contralateral knee
Worst daily pain (11-point NRS), Contralateral knee(Score on a scale)G001 Topical GelVehicle Topical GelTotal
Mean1.1 ± 0.780.9 ± 0.811.0 ± 0.80
Kellgren and Lawrence Grading
Kellgren and Lawrence Grading(Participants)G001 Topical GelVehicle Topical GelTotal
KL Grade 2465399
KL Grade 35952111
08

Study locations

10 sites
  • Aggarwal and Associates Limited
    Brampton, Canada
  • Manna Research
    Lévis, Canada
  • Recherche GCP Research
    Montréal, Canada
  • Alpha recherche Clinique (1)
    Quebec City, Canada
  • Alpha Recherche Clinique (2)
    Quebec City, Canada
  • Centre de Recherche Saint-Louis
    Quebec City, Canada
  • G.R.M.O. (Groupe de Recherche en Maladie Osseuses) Inc.
    Quebec City, Canada
  • Recherche Clinique Sigma Inc.
    Quebec City, Canada
  • Medicor Research Inc.
    Sudbury, Canada
  • Canadian Phase Onward Inc.
    Toronto, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jan 2023, 23 months.

Results were first posted in Apr 2024, 1 year 3 months after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 23 months is above that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2021
First posted
Aug 16, 2021
StartActual
Jan 6, 2021
Primary completionActual
Jan 4, 2023
CompletionActual
Jan 10, 2023
Results first posted
Apr 23, 2024
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05007808
Lead sponsor
BUZZZ Pharmaceuticals Limited
Collaborators
Veristat, Inc.
Responsible party
Sponsor
First posted
Aug 16, 2021
Start date
Jan 6, 2021
Primary completion
Jan 4, 2023
Completion
Jan 10, 2023
Results posted
Apr 23, 2024
Last update
Apr 23, 2024

Study contacts

Deirdre O'Keeffe, PhD
study director · Buzzz Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion